Lupin is planning to expand its footprint in Europe by acquiring generics manufacturers for as much as $1 billion. The company is eying those entities that are capable in complex generics like inhalation products and injectables, dermatology products and biosimilar drugs.
Real Time News & Trading Trends Keep Liking Epic Research Private Limited
Facebook – Twitter – YouTube – Pinterest –Linkedin - Google+
For more information ✆ – 0731-6642300 or Visit http://ift.tt/1k8NnLH
0 comments:
Post a Comment